Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation develops infectious-disease therapeutics centered on chronic hepatitis B, including imdusiran (AB-729), a GalNAc-conjugated RNAi therapeutic, and AB-101, an oral PD-1 inhibitor. News for ABUS commonly covers clinical data, regulatory designations such as FDA Fast Track for imdusiran, scientific-meeting abstracts, and corporate updates tied to the company’s cHBV programs.
Recurring coverage also includes financial results, capital-allocation updates, licensing revenue from lipid nanoparticle technology, and intellectual-property developments involving Arbutus and its licensee Genevant Sciences. The company’s LNP delivery technology and related patent matters are a recurring business theme alongside its clinical-stage antiviral pipeline.
WARMINSTER, Pa., Sept. 06, 2022 – Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13 at 12:30 PM ET, with CEO William Collier as the presenter. Additionally, they will hold a fireside chat at Baird's 2022 Global Healthcare Conference on September 14 at 10:15 AM ET. Live webcasts will be available on their website, with replays accessible post-event.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the issuance of U.S. Patent No. 11,427,823 by the USPTO, granting composition of matter protection for its AB-729 RNAi therapeutic. This patent extends exclusivity for AB-729 until at least April 2038. The company is advancing AB-729 through multiple Phase 2a clinical trials, showing promising safety and efficacy, with significant reductions in hepatitis B surface antigen and DNA levels. Arbutus aims to address the unmet medical needs of over 290 million chronic hepatitis B virus patients globally.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported their second quarter 2022 financial results, showing a strong financial position with cash and equivalents of $200.6 million, ensuring a runway into Q2 2024. Revenue surged to $14.2 million, up from $2.3 million a year earlier, primarily due to a license agreement with Qilu Pharmaceutical. Clinical advancements were made in their hepatitis B and pan-coronavirus programs, including promising data from their lead therapies AB-729 and AB-836. The company remains focused on its pipeline and upcoming trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2022 financial results and corporate update on August 4, 2022. The company will release its Q2/2022 press release at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through the Investors section of Arbutus' website. The company focuses on innovative therapeutics for viral diseases, including Hepatitis B and coronaviruses, and is advancing its lead compound, AB-729, in multiple phase 2 clinical trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the continuation of its Phase 2a clinical trial evaluating AB-729, an RNAi therapeutic, in combination with Assembly Biosciences' discontinued vebicorvir and nucleos(t)ide analogue for chronic HBV infection. Despite Assembly's decision to halt VBR development, Arbutus intends to continue patient dosing, with preliminary data expected in the second half of 2022. AB-729 is positioned as a cornerstone in potential HBV treatments, aiming for significant reductions in viral biomarkers.
Arbutus Biopharma (Nasdaq: ABUS) presented promising data at the EASL International Liver Congress regarding its pipeline for chronic hepatitis B (cHBV). Key findings include AB-729, which demonstrated significant HBsAg declines in 50% of patients, with sustained virologic control after treatment cessation. AB-836 showed mean declines in HBV DNA, but safety concerns arose in a subset. The company plans further trials for both AB-836 and AB-101, an oral PD-L1 inhibitor, indicating a strong commitment to advancing therapies for cHBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that seven abstracts have been accepted for poster presentations at the EASL International Liver Congress™ 2022, scheduled for June 22-26, 2022, in London. The presentations will focus on Viral Hepatitis B/D therapy and highlight new data from trials involving AB-729 and AB-836. A conference call is set for June 27, 2022, at 8:00 am ET to discuss these findings. Key studies presented include significant progress in HBsAg suppression and long-term antiviral effects.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) announced the dosing of the first patient in a Phase 2a clinical trial evaluating the RNAi therapeutic AB-729 in combination with VTP-300 and nucleos(t)ide reverse transcriptase inhibitor therapy, targeting chronic HBV infection. The trial will enroll 40 patients to assess safety and antiviral activity. AB-729 aims to reduce HBV viral proteins, potentially reawakening the immune system. This collaboration seeks to improve HBsAg reduction and T-cell responses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. The Jefferies Healthcare Conference will take place from June 8-10, 2022, featuring a fireside chat with key executives on June 9 at 3:00 pm ET. The JMP Securities Life Sciences Conference is scheduled for June 15-16, 2022, with a fireside chat on June 15 at 9:00 am ET. Live webcasts can be accessed via the company's website. Arbutus specializes in developing therapeutics for viral diseases, including Hepatitis B and coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that its abstract on a preclinical oncology study of an oral PD-L1 inhibitor will be published at the ASCO Annual Meeting on June 3-7, 2022. The abstract titled "Pre-clinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors" focuses on the compound's potential to stimulate the immune system. This publication may enhance Arbutus' visibility in oncology, complementing its efforts in viral diseases like Hepatitis B and SARS-CoV-2.